Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab

Rohit Aggarwal, Priyadarshini Loganathan, Diane Koontz, Zengbiao Qi, Ann M. Reed, Chester V. Oddis

Research output: Contribution to journalArticle

Abstract

Objective. The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM. Methods. Patients with refractory adult DM (n = 72) and JDM (n = 48) were treated with rituximab in a randomized placebo-phase-controlled trial [either rituximab early drug (week 0/1) or rituximab late arms (week 8/9), such that all subjects received study drug]. Stable concomitant therapy was allowed. Cutaneous disease activity was assessed using the Myositis Disease Activity Assessment Tool, which grades cutaneous disease activity on a visual analog scale. A myositis damage assessment tool, termed the Myositis Damage Index, was used to assess cutaneous damage. Improvement post-rituximab was evaluated in individual rashes as well as in cutaneous disease activity and damage scores. The χ2 test, Student's paired t-test and Wilcoxon test were used for analysis. Results. There were significant improvements in cutaneous disease activity from baseline to the end of the trial after rituximab administration in both adult DM and JDM subsets. The cutaneous visual analog scale activity improved in adult DM (3.22-1.72, P = 0.0002) and JDM (3.26-1.56, P < 0.0001), with erythroderma, erythematous rashes without secondary changes of ulceration or necrosis, heliotrope, Gottron sign and papules improving most significantly. Adult DM subjects receiving rituximab earlier in the trial demonstrated a trend for faster cutaneous response (20% relative improvement from baseline) compared with those receiving B cell depletion later (P = 0.052). Conclusion. Refractory skin rashes in adult DM and JDM showed improvement after the addition of rituximab to the standard therapy in a clinical trial.

Original languageEnglish (US)
Pages (from-to)247-254
Number of pages8
JournalRheumatology (United Kingdom)
Volume56
Issue number2
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Skin
Skin Diseases
Myositis
Exanthema
Therapeutics
Visual Analog Scale
Exfoliative Dermatitis
Skin Manifestations
Juvenile dermatomyositis
Rituximab
Pharmaceutical Preparations
B-Lymphocytes
Necrosis
Placebos
Clinical Trials
Students

Keywords

  • B cell depletion
  • Cutaneous
  • Dermatomyositis
  • Juvenile dermatomyositis
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. / Aggarwal, Rohit; Loganathan, Priyadarshini; Koontz, Diane; Qi, Zengbiao; Reed, Ann M.; Oddis, Chester V.

In: Rheumatology (United Kingdom), Vol. 56, No. 2, 01.01.2017, p. 247-254.

Research output: Contribution to journalArticle

Aggarwal, Rohit ; Loganathan, Priyadarshini ; Koontz, Diane ; Qi, Zengbiao ; Reed, Ann M. ; Oddis, Chester V. / Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. In: Rheumatology (United Kingdom). 2017 ; Vol. 56, No. 2. pp. 247-254.
@article{524d1e1985b14fd59c8c0e202c332390,
title = "Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab",
abstract = "Objective. The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM. Methods. Patients with refractory adult DM (n = 72) and JDM (n = 48) were treated with rituximab in a randomized placebo-phase-controlled trial [either rituximab early drug (week 0/1) or rituximab late arms (week 8/9), such that all subjects received study drug]. Stable concomitant therapy was allowed. Cutaneous disease activity was assessed using the Myositis Disease Activity Assessment Tool, which grades cutaneous disease activity on a visual analog scale. A myositis damage assessment tool, termed the Myositis Damage Index, was used to assess cutaneous damage. Improvement post-rituximab was evaluated in individual rashes as well as in cutaneous disease activity and damage scores. The χ2 test, Student's paired t-test and Wilcoxon test were used for analysis. Results. There were significant improvements in cutaneous disease activity from baseline to the end of the trial after rituximab administration in both adult DM and JDM subsets. The cutaneous visual analog scale activity improved in adult DM (3.22-1.72, P = 0.0002) and JDM (3.26-1.56, P < 0.0001), with erythroderma, erythematous rashes without secondary changes of ulceration or necrosis, heliotrope, Gottron sign and papules improving most significantly. Adult DM subjects receiving rituximab earlier in the trial demonstrated a trend for faster cutaneous response (20{\%} relative improvement from baseline) compared with those receiving B cell depletion later (P = 0.052). Conclusion. Refractory skin rashes in adult DM and JDM showed improvement after the addition of rituximab to the standard therapy in a clinical trial.",
keywords = "B cell depletion, Cutaneous, Dermatomyositis, Juvenile dermatomyositis, Rituximab",
author = "Rohit Aggarwal and Priyadarshini Loganathan and Diane Koontz and Zengbiao Qi and Reed, {Ann M.} and Oddis, {Chester V.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/rheumatology/kew396",
language = "English (US)",
volume = "56",
pages = "247--254",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab

AU - Aggarwal, Rohit

AU - Loganathan, Priyadarshini

AU - Koontz, Diane

AU - Qi, Zengbiao

AU - Reed, Ann M.

AU - Oddis, Chester V.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective. The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM. Methods. Patients with refractory adult DM (n = 72) and JDM (n = 48) were treated with rituximab in a randomized placebo-phase-controlled trial [either rituximab early drug (week 0/1) or rituximab late arms (week 8/9), such that all subjects received study drug]. Stable concomitant therapy was allowed. Cutaneous disease activity was assessed using the Myositis Disease Activity Assessment Tool, which grades cutaneous disease activity on a visual analog scale. A myositis damage assessment tool, termed the Myositis Damage Index, was used to assess cutaneous damage. Improvement post-rituximab was evaluated in individual rashes as well as in cutaneous disease activity and damage scores. The χ2 test, Student's paired t-test and Wilcoxon test were used for analysis. Results. There were significant improvements in cutaneous disease activity from baseline to the end of the trial after rituximab administration in both adult DM and JDM subsets. The cutaneous visual analog scale activity improved in adult DM (3.22-1.72, P = 0.0002) and JDM (3.26-1.56, P < 0.0001), with erythroderma, erythematous rashes without secondary changes of ulceration or necrosis, heliotrope, Gottron sign and papules improving most significantly. Adult DM subjects receiving rituximab earlier in the trial demonstrated a trend for faster cutaneous response (20% relative improvement from baseline) compared with those receiving B cell depletion later (P = 0.052). Conclusion. Refractory skin rashes in adult DM and JDM showed improvement after the addition of rituximab to the standard therapy in a clinical trial.

AB - Objective. The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM. Methods. Patients with refractory adult DM (n = 72) and JDM (n = 48) were treated with rituximab in a randomized placebo-phase-controlled trial [either rituximab early drug (week 0/1) or rituximab late arms (week 8/9), such that all subjects received study drug]. Stable concomitant therapy was allowed. Cutaneous disease activity was assessed using the Myositis Disease Activity Assessment Tool, which grades cutaneous disease activity on a visual analog scale. A myositis damage assessment tool, termed the Myositis Damage Index, was used to assess cutaneous damage. Improvement post-rituximab was evaluated in individual rashes as well as in cutaneous disease activity and damage scores. The χ2 test, Student's paired t-test and Wilcoxon test were used for analysis. Results. There were significant improvements in cutaneous disease activity from baseline to the end of the trial after rituximab administration in both adult DM and JDM subsets. The cutaneous visual analog scale activity improved in adult DM (3.22-1.72, P = 0.0002) and JDM (3.26-1.56, P < 0.0001), with erythroderma, erythematous rashes without secondary changes of ulceration or necrosis, heliotrope, Gottron sign and papules improving most significantly. Adult DM subjects receiving rituximab earlier in the trial demonstrated a trend for faster cutaneous response (20% relative improvement from baseline) compared with those receiving B cell depletion later (P = 0.052). Conclusion. Refractory skin rashes in adult DM and JDM showed improvement after the addition of rituximab to the standard therapy in a clinical trial.

KW - B cell depletion

KW - Cutaneous

KW - Dermatomyositis

KW - Juvenile dermatomyositis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85039809702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039809702&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kew396

DO - 10.1093/rheumatology/kew396

M3 - Article

VL - 56

SP - 247

EP - 254

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 2

ER -